FY2025 EPS Estimates for Galectin Therapeutics Inc. Lowered by Analyst (NASDAQ:GALT)

Galectin Therapeutics Inc. (NASDAQ:GALT) – Research analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of Galectin Therapeutics in a report released on Monday, April 1st. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of ($1.59) for the year, down from their previous estimate of ($1.37). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ FY2026 earnings at ($0.97) EPS and FY2027 earnings at $1.32 EPS.

Separately, StockNews.com upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday.

Galectin Therapeutics Trading Up 5.3 %

Shares of NASDAQ GALT opened at $3.00 on Thursday. The firm has a market capitalization of $185.70 million, a PE ratio of -4.05 and a beta of 0.84. Galectin Therapeutics has a 1 year low of $1.28 and a 1 year high of $3.00. The firm’s 50-day moving average is $2.00 and its 200-day moving average is $1.93.

Institutional Trading of Galectin Therapeutics

A number of hedge funds have recently modified their holdings of GALT. PNC Financial Services Group Inc. raised its position in shares of Galectin Therapeutics by 21.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 56,184 shares of the company’s stock valued at $90,000 after acquiring an additional 10,000 shares during the period. Centaurus Financial Inc. acquired a new stake in shares of Galectin Therapeutics in the 1st quarter valued at approximately $34,000. Atria Wealth Solutions Inc. acquired a new stake in shares of Galectin Therapeutics in the 1st quarter valued at approximately $460,000. State Street Corp raised its holdings in Galectin Therapeutics by 9.4% during the 1st quarter. State Street Corp now owns 173,740 shares of the company’s stock worth $280,000 after buying an additional 14,981 shares during the period. Finally, MML Investors Services LLC raised its holdings in Galectin Therapeutics by 28.4% during the 3rd quarter. MML Investors Services LLC now owns 49,777 shares of the company’s stock worth $81,000 after buying an additional 11,000 shares during the period. 11.68% of the stock is currently owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.